Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial

Variation in de-adoption of ineffective or unsafe treatments is not well-understood. We examined de-adoption of erythropoiesis-stimulating agents (ESA) in anemia treatment among patients with chronic kidney disease (CKD) following new clinical evidence of harm and ineffectiveness (the TREAT trial) and the FDA's revision of its safety warning.We used a segmented regression approach to estimate changes in use of epoetin alfa (EPO) and darbepoetin...